Truist downgraded Editas Medicine (EDIT) to Hold from Buy. The company shared a significant strategic update notable for ending reni-cel development and 65% reduction in workforce, the analyst tells investors in a research note. The firm said that, given rapidly evolving competitive dynamics, it’s difficult to have a view on Editas’ in vivo program at this juncture. Due to the lack of a clear path to value creating catalysts in the next 12-18 months, Truist is choosing to stay on the sidelines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine downgraded to Hold from Buy at Stifel
- Editas Medicine Shifts Focus to In Vivo Gene Editing
- Editas to reduce workforce by 65%, announces departure of CMO Baisong Mei
- Editas Medicine downgraded to Equal Weight from Overweight at Wells Fargo
- Editas Medicine Updates RUBY Trial with Promising Results